Gene Amplification and Expression of the Steroid Receptor Coactivator SRC3 (AIB1) in Sporadic Breast and Endometrial Carcinomas

 

 Buy Article Permissions and Reprints

Steroid receptor coactivator 3 (SRC3) functions as a coactivator for nuclear receptor mediated transcriptional activation. It binds to nuclear receptors in a ligand-dependent fashion and recruits other factors such as CBP and p300 to the transactivation complex. Due to its function as activator of nuclear receptors, overexpression of SRC3 might enhance their effects. Gene amplification is a common mechanism that causes overexpression, already described for oncogenes like c-erbB2, c-myc and int2. In this study, SRC3 gene amplification and expression levels were analyzed in 127 sporadic breast carcinomas, 30 endometrial carcinomas and different cell lines (MCF7, HeLa, Ishikawa, T47D, BT-20, SK-BR-3, HEC-1a, RL 95 - 2, OVCAR3 and A-431). To determine gene amplification and mRNA expression levels, quantitative differential PCR and RT-PCR were performed in combination with fluorescent DNA technology. Gene amplification was not found in any of the breast and endometrial carcinomas, but was found in the carcinoma cell lines MCF7 (10-fold) and HeLa (3-fold). SRC3 overexpression was detected in 13 % (3/23) of breast carcinomas and 17 % (5/30) of endometrial carcinomas, as well as in MCF7 and HeLa cells. Thus, SRC3 overexpression found in breast and endometrial tumors is not caused by SRC3 gene amplification. A carcinogenic potential provided by SRC3 overexpression has to be elucidated in further studies.

References

• 1 Voegel J J, Heine M JS, Zechel C, Chambon P, Gronemeyer H. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors.  EMBO J. 1996;  15 3667-3675
  PubMedGoogle Scholar
• 2 Anzick S L, Kononen J, Walker R L, Azorsa D O, Tanner M N, Guan X -Y, Sauter G, Kallioniemi O -P, Trent J M, Meltzer P S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.  Science. 1997;  277 965-968
  CrossrefPubMedGoogle Scholar
• 3 Li H, Gomes P J, Chen J D. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. .  Proc Natl Acad Sci USA. 1997;  94 8479-8484
  CrossrefPubMedGoogle Scholar
• 4 Chen H, Lin R J, Schiltz R L, Chakravarti D, Nash A, Nagy L, Privalsky M L, Nakatani Y, Evans R M. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with p/CAF and CBP/p300.  Cell. 1997;  90 569-580
  CrossrefPubMedGoogle Scholar
• 5 Torchia J, Rose D W, Inostroza J, Kamei Y, Westin S, Glass C K, Rosenfeld M G. The transciptional co-activator p/CIP binds CBP and mediates nuclear receptor function.  Nature. 1997;  387 677-684
  CrossrefPubMedGoogle Scholar
• 6 Takeshita A, Cardona G R, Koibuchi N, Suen C -S, Chin W W. TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1.  J Biol Chem. 1997;  272 27 629-27 634
  PubMedGoogle Scholar
• 7 Beckmann M W, Niederacher D, Schnürch H -G, Gusterson B A, Bender H G. Multistep carcinogenesis of breast cancer and tumour heterogeneity.  J Mol Med. 1997;  75 429-439
  CrossrefPubMedGoogle Scholar
• 8 An H -X, Niederacher D, Beckmann M W, Göhring U -J, Scharl A, Picard F, van Roeyen C, Schnürch H -G, Bender H G. ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues.  Int J Cancer (Pred.Oncol.). 1995;  64 291-297
  PubMedGoogle Scholar
• 9 Berns E MJJ, Klijn J GM, van Staveren I L, Protengen H, Noordegraaf E, Foekens J A. Prevalence of amplification of the oncogenes c-myc, Her2/neu, and int-2 in one thousand human breast tumors: Correlation with steroid receptors.  Eur J Cancer. 1992a;  28 697-700
  PubMedGoogle Scholar
• 10 Berns E MJJ, Foekens J A, van Putten W LJ, van Staveren I L, Protengen H, De Konin W CH, Klijn J GM. Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification.  J Steroid Biochem Mol Biol. 1992b ;  43 13-19
  CrossrefPubMedGoogle Scholar
• 11 Niederacher D, An H -X, Cho Y -J, Hantschmann P, Bender H G, Beckmann M W. Mutations and amplifications of oncogenes in endometrial cancer.  Oncology. 1999;  56 59-65
  PubMedGoogle Scholar
• 12 Ross J S, Fletcher J A. The HER-2/neu oncogene in breast cancer: Prognostic factor, predicitve factor, and target for therapy.  The Oncologist. 1998;  3 237-252
  PubMedGoogle Scholar
• 13 Revillion F, Bonneterre J, Peyrat J P. ERBB2 Oncogene in human breast cancer and its clinical significance.  Eur J Cancer. 1998;  34 791-808
  CrossrefPubMedGoogle Scholar
• 14 Tavassoli M, Quirke P, Farzaneh F, Lock N J, Mayne L V, Kirkham N. c-erbB2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumor grade, in human breast carcinoma.  Br J Cancer. 1989;  60 505-510
  PubMedGoogle Scholar
• 15 Bautista S, Valles H, Walker R L, Anzick S, Zeillinger R, Meltzer P, Theillet C. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity.  Clin Cancer Res. 1998;  4 2925-2929
  PubMedGoogle Scholar
• 16 Beckmann M W, Tutschek B, Göhring U J, Engels K, Picard F, Scharl A, Niederacher D, Schnürch H G. Immunohistochemical detection of epidermal growth factor receptor (EGF-R) in paraffin sections of breast carcinoma tissue. Correlation and clinical significance.  Geburtshilfe Frauenheilkd. 1995;  55 258-265
  PubMedGoogle Scholar
• 17 Liu E T, He M, Rajgopal U. Differential polymerase chain reaction in the analysis of gene dosage.  Semin Cancer Biol. 1993;  4 47-58
  PubMedGoogle Scholar
• 18 An H -X, Niederacher D, Dominik S I, Kuschel B, Yan H, Dall P, Schnürch H -G, Bender H G, Beckmann M W. int-2 and c-erbB-2 gene amplification detected in 70 frozen human human breast carcinomas by quantitative polymerase chain reaction.  Anticancer Research. 1997;  17 3133-3136
  PubMedGoogle Scholar
• 19 Schulte K M, Niederacher D, An H X, Staudt S, Simon D, Beckmann M W, Goretzki P E. INT-2 gene amplification in differentiated human thyroid cancer.  Exp Clin Endocrinol Diabetes. 1996;  104 (Suppl. 4) 101-104
  PubMedGoogle Scholar
• 20 Ghadimi B M, Schrock E, Walker R L, Wangsa D, Jauho A, Meltzer P S, Ried T. Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.  Am J Pathol. 1999;  154 525-536
  PubMedGoogle Scholar
• 21 An H X, Beckmann M W, Reifenberger G, Bender H G, Niederacher D. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation.  Am J Pathol. 1999;  154 113-118
  PubMedGoogle Scholar
• 22 Tanner M M, Tirkkonen M, Kallioniemi A, Holli K, Collins C, Kowbel D, Gray J W, Kallioniemi O -P, Isola J. Amplification of chromosomal region 20q13 in invasive breast cancer: Prognostic implication.  Clin Cancer Res. 1995;  1 1455-1461
  PubMedGoogle Scholar
• 23 Sheppard K A, Phelps K M, Williams A J, Thanos D, Glass C K, Rosenfeld M G, Gerritsen M E, Collins T. Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1.  J Biol Chem. 1998;  273 29 291-29 294
  PubMedGoogle Scholar
• 24 Kamei Y, Lan X, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin S -C, Heymann R A, Rose D W, Glass C K, Rosenfeld M G. A CBP integrator complex mediates transcriptional activation and AP1-inhibition by nuclear receptors.  Cell. 1996;  85 403-414
  CrossrefPubMedGoogle Scholar

Dr. D. Niederacher

Department of Gynecology and Obstetrics
Heinrich-Heine-University
Molekulargenetisches Labor

Moorenstrasse 5
40225 Duesseldorf
Germany


Phone: Phone:+ 49 (211) 81-15319

Fax: Fax:+ 49 (211) 81-15319

Email: E-mail:niederac@uni-duesseldorf.de